Chemotherapy drug beats remdesivir against Covid in lab tests: Study Kumar Jeetendra | January 3, 2021 A chemotherapy medication originally developed to treat cancer might potentially be repurposed to inhibit the replication of the novel coronavirus and cure COVID-19, according to a study based on computer simulations and laboratory experiments. The study, published in the journal PLOS Computational Biology, combined multiple computational methods that simulate drug-virus interactions from different, complimentary perspectives. …
An incredible achievement in India’s’ scientific fraternity capacity: Bharat Biotech on endorsement for emergency use of covaxin Kumar Jeetendra | January 3, 2021 Hyderabad, Jan 3 (PTI): Expressing delight over the approval on restricted emergency use of its COVID-19 vaccine Covaxin, Bharat Biotech on Sunday said it has generated excellent safety data with robust immune responses to multiple viral proteins that persist and their goal is to provide global access to populations that need it the most. Ella …
Russia prepared to trial combined AstraZeneca, Sputnik V antibody in Ukraine Kumar Jeetendra | January 3, 2021 Russia is ready to run clinical trials in Ukraine of a COVID-19 vaccine combining its Sputnik V with a vaccine developed by AstraZeneca together with Oxford University, the head of Russian Direct Investment Fund (RDIF) said on Saturday. Russia’s autonomous RDIF, which is marketing the Sputnik V vaccine overseas, announced in December trials to test …
Emergency use SEC approval for Bharat Biotech Covaxin Kumar Jeetendra | January 2, 2021 The SEC has recommended Covaxin for emergency use authorisation (EUA), reported news agency ANI quoting government sources. The recommendation, together with rollout modalities, will be taken up from the Drug Controller General of India (DCGI) to get a final decision on the issue. The Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO) …
AstraZeneca expects to supply 2 million doses of COVID-19 vaccine each week in UK: Report Kumar Jeetendra | January 2, 2021 Approximately two million doses of COVID-19 vaccine developed by Oxford University and AstraZeneca are set to be supplied each week from the middle of January in the United Kingdom, The Times reported. AstraZeneca expects to supply two million doses of the vaccine in total by next week, the paper reported, citing an unnamed member of …
Pfizer and BioNTech to offer COVID-19 immunization to volunteers who got fake treatment Kumar Jeetendra | January 2, 2021 Pfizer Inc and its partner BioNTech Se plan to provide volunteers who received a placebo in its COVID-19 vaccine trial an option to receive a first dose of the vaccine by March 1, 2021, while staying within the study. The trial’s Vaccine Transition Option permits all participants aged 16 or older the choice to discover …
New UCLA-formed gadget moves mitochondria into at least 100,000 or more beneficiary cells Kumar Jeetendra | January 1, 2021 Scientists from the UCLA Jonsson Comprehensive Cancer Center have developed a simple, high-throughput way of transferring isolated mitochondria and their associated mitochondrial DNA into mammalian cells. This approach enables researchers to tailor a key genetic component of cells, to study and potentially treat debilitating diseases such as cancer, diabetes and metabolic disorders. A study, published …
WHO clears Covid immunization for emergency use Kumar Jeetendra | January 1, 2021 The World Health Organization says it has cleared the Pfizer-BioNTech coronavirus vaccine for emergency use, meaning poorer countries may soon get access to the shooter already available in Europe and North America. Every country which has a drug regulatory agency will need to issue its own approval for any COVID-19 vaccine, but states with weak …
Sustainable immune dysregulation because of COVID-19 in non-hospitalized patients Kumar Jeetendra | December 31, 2020 COVID-19, which has killed 1.7 million people globally, doesn’t follow a uniform path. Others, especially those with comorbidities, can create severe clinical disease with atypical pneumonia and multiple system organ failure. Since the first cases were reported in December 2019, the SARS-CoV-2 virus that causes COVID-19 has surged into a pandemic, with cases and deaths …
Older adults, minorities and individuals with lower salaries face disparities in telemedicine use Kumar Jeetendra | December 31, 2020 After”COVID-19,” the word which most people will remember best from 2020 is very likely to be”social distancing.” While it most commonly applied to social gatherings with family and friends, it has changed how many receive medical attention. However, the COVID-19 pandemic, particularly in the spring of 2020, required increased use of virtual or telephone call …
Russia to convey more than 1 million Sputnik V shots at home by year-end: Minister Kumar Jeetendra | December 31, 2020 Russia will have supplied more than 1 million doses of its COVID-19 vaccine Sputnik V to its own national inoculation programme by the end of the year, a government minister said on Wednesday. Russia, which started rolling out the vaccine in early December, has thus far produced more than 2 million doses in total, Industry …
Moderna COVID-19 antibody shows 94.1% adequacy in preliminary: Study Kumar Jeetendra | December 31, 2020 Results from the primary analysis of the ongoing phase 3 clinical trial of US biotechnology company Moderna’s COVID-19 vaccine have revealed 94.1 per cent effectiveness of the therapeutic in preventing symptomatic infections and severe illness, according to a peer-reviewed study. The analysis, published on Wednesday in The New England Journal of Medicine, found that among …
